Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis - PubMed
5 hours ago
- #CKM syndrome
- #Finerenone
- #Sex differences
- Study examines sex differences in cardiovascular-kidney-metabolic (CKM) syndrome using pooled data from three trials.
- Women (35% of participants) were slightly older and had lower urine albumin-to-creatinine ratios compared to men.
- Women were more likely to have Stage 4 CKM syndrome but less likely to receive standard CKM therapies at baseline.
- Rates of HF hospitalization or cardiovascular death were similar between sexes, but women had lower all-cause mortality risk.
- Finerenone showed consistent benefits in both women and men, with no evidence of treatment heterogeneity by sex.
- Findings highlight persistent sex-based disparities in CKM care despite similar treatment efficacy.